ERBB2 and breast carcinoma: If ongoing larger trials (e.g. CompassHER2-pCR) demonstrate favorable long-term efficacy associated with this treatment approach, then the majority of patients with anatomic stage II-III HER2+ breast cancer may be able to avoid the substantial toxicities associated with standard combined chemotherapy regimens.